NZ595351A - Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use - Google Patents
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and useInfo
- Publication number
- NZ595351A NZ595351A NZ595351A NZ59535106A NZ595351A NZ 595351 A NZ595351 A NZ 595351A NZ 595351 A NZ595351 A NZ 595351A NZ 59535106 A NZ59535106 A NZ 59535106A NZ 595351 A NZ595351 A NZ 595351A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- dependent cellular
- production
- methods
- enhanced antibody
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 230000001413 cellular effect Effects 0.000 title 1
- 231100000135 cytotoxicity Toxicity 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A composition comprising antibodies, wherein the antibodies have enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, wherein the antibodies are from non-human mammalian mammary epithelial cells engineered to express the antibody, wherein the ADCC activity of the antibodies is enhanced at least two-fold compared to cell-culture derived antibodies, wherein the carbohydrates of the antibodies exhibit a high mannose glycosylation pattern, wherein at least 30% of the antibodies contain at least one oligomannose, and wherein the antibodies are of the isotype IgG1 or IgG2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2005729054 | 2005-10-21 | ||
| NZ568433A NZ568433A (en) | 2005-10-21 | 2006-10-23 | Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595351A true NZ595351A (en) | 2015-06-26 |
Family
ID=53490963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595351A NZ595351A (en) | 2005-10-21 | 2006-10-23 | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ595351A (en) |
-
2006
- 2006-10-23 NZ NZ595351A patent/NZ595351A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60334700D1 (en) | ADCC-RELATED ANTIBODIES TO HLA-DR INDUCING THE PRODUCTION OF CYTOKINS | |
| WO2006089231A3 (en) | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues | |
| SG170006A1 (en) | Monoclonal antibodies against cd30 lacking fucosyl residues | |
| NZ592859A (en) | Multivariable antigens complexed with targeting humanized monoclonal antibody | |
| PL1674111T3 (en) | Anti-glypican 3 antibody | |
| WO2007084672A3 (en) | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues | |
| DE60236016D1 (en) | CELLULAR COMPOSITIONS AND METHOD FOR THE PREPARATION AND USE THEREOF | |
| MXPA03002974A (en) | Cells producing antibody compositions. | |
| UA95284C2 (en) | Antibodies against insulin-like growth factor i receptor and uses thereof | |
| NZ572756A (en) | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody | |
| SG159392A1 (en) | Humanized anti-cd4 antibody with immunosuppressive properties | |
| EP2620450A3 (en) | Anti-CTLA-4 antibody compositions | |
| DK2180007T3 (en) | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity | |
| ATE459653T1 (en) | MONOCLONAL ANTI-CD71 ANTIBODIES AND THEIR USE FOR TREATING MALIGNANT TUMOR CELLS | |
| EA200971056A1 (en) | PRODUCTION OF RECOMBINANT PROTEINS IN EBX® BIRD CELLS | |
| MX2010002248A (en) | Anti-epha2 antibody. | |
| WO2007084922A3 (en) | Compositions and methods for humanization and optimization of n-glycans in plants | |
| IL194221A (en) | Humanized monoclonal antibodies to hepatocyte growth factor, cell lines for production of the antibodies and pharmaceutical compositions comprising the antibodies | |
| WO2008052030A3 (en) | A method for increasing antibody-dependent cytotoxicity with castanospermine | |
| WO2007082715A3 (en) | Anti-cd19 antibody composition and method | |
| WO2008054522A3 (en) | Room temperature synthesis of gan nanopowder | |
| EP1930346A4 (en) | ANTIBODY OBTAINED BY USING AN OSTRICH AND METHOD FOR PRODUCING THE SAME | |
| WO2007062056A3 (en) | Silicon-germanium hydrides and methods for making and using same | |
| EA201171133A1 (en) | HUMANIZED ANTIBODIES WITH ANTI-TUMOR ACTIVITY | |
| NZ595351A (en) | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: LFB USA, INC., US Effective date: 20141016 Owner name: GENZYME CORPORATION, US Effective date: 20141016 |
|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |